ANI Pharmaceuticals Inc. (ANIP) and Cara Therapeutics Inc. (NASDAQ:CARA) Comparison side by side

This is therefore a comparing of the analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation in ANI Pharmaceuticals Inc. (NASDAQ:ANIP) and Cara Therapeutics Inc. (NASDAQ:CARA). The two are both Biotechnology companies that compete with one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ANI Pharmaceuticals Inc. 67 4.71 N/A 1.30 53.14
Cara Therapeutics Inc. 19 57.59 N/A -2.10 0.00

We can see in table 1 the earnings per share, gross revenue and valuation of ANI Pharmaceuticals Inc. and Cara Therapeutics Inc.


Table 2 shows us ANI Pharmaceuticals Inc. and Cara Therapeutics Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ANI Pharmaceuticals Inc. 0.00% 0.2% 0.1%
Cara Therapeutics Inc. 0.00% -67.3% -44.4%

Volatility & Risk

ANI Pharmaceuticals Inc. has a 2.33 beta, while its volatility is 133.00%, thus making it more volatile than S&P 500. Cara Therapeutics Inc.’s 2.63 beta is the reason why it is 163.00% more volatile than S&P 500.


The Current Ratio and Quick Ratio of ANI Pharmaceuticals Inc. are 0.9 and 0.7 respectively. Its competitor Cara Therapeutics Inc.’s Current Ratio is 3.4 and its Quick Ratio is 3.4. Cara Therapeutics Inc. can pay off short and long-term obligations better than ANI Pharmaceuticals Inc.

Analyst Ratings

ANI Pharmaceuticals Inc. and Cara Therapeutics Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
ANI Pharmaceuticals Inc. 0 0 3 3.00
Cara Therapeutics Inc. 0 0 6 3.00

ANI Pharmaceuticals Inc. has an average target price of $75, and a -7.69% downside potential. Meanwhile, Cara Therapeutics Inc.’s consensus target price is $26.86, while its potential upside is 3.87%. The data from earlier shows that analysts belief suggest that Cara Therapeutics Inc. seems more appealing than ANI Pharmaceuticals Inc.

Institutional & Insider Ownership

Roughly 82.7% of ANI Pharmaceuticals Inc. shares are held by institutional investors while 60.7% of Cara Therapeutics Inc. are owned by institutional investors. Insiders held 3.7% of ANI Pharmaceuticals Inc. shares. Insiders Comparatively, held 2.7% of Cara Therapeutics Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ANI Pharmaceuticals Inc. -2.62% 1.01% 17.95% 31.3% 12.75% 53.58%
Cara Therapeutics Inc. -2.2% -3.76% 11.84% -4.88% 47.79% 43.92%

For the past year ANI Pharmaceuticals Inc. was more bullish than Cara Therapeutics Inc.


On 6 of the 9 factors ANI Pharmaceuticals Inc. beats Cara Therapeutics Inc.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for pain; Propafenone to treat arrhythmia; Propranolol ER and Inderal LA for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. It is developing product candidates that target the body's peripheral nervous system. The companyÂ’s lead product candidate comprises I.V. CR845, which is in Phase III clinical trials for the treatment of patients with acute postoperative pain in adult patients, as well as in Phase II/III clinical trial for the treatment of uremic pruritus disease. It is also developing Oral CR845 that is in Phase IIb clinical trial to treat moderate-to-severe acute and chronic pain, as well as in Phase I clinical trial to treat uremic pruritus; and CR701, which is in preclinical trial for the treatment of neuropathic and inflammatory pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845 for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845 in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.